https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-7d2cc969f2df410bPharma Surgeen2026-07-06T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/endo-operations-limited-et-al-withdrawal-of-approval-of-34-new-drug-applications-0fe04ab6d448b9fcPharma Surgeen2026-07-06T00:00:00.000ZEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applicationshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-199f19173a542002Pharma Surgeen2026-07-06T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/temporary-placement-of-7-hydroxymitragynine-above-a-specified-threshold-in-sched-92546f760ae2e0f2Pharma Surgeen2026-07-06T00:00:00.000ZTemporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I; Request for Informationhttps://www.pharmaradar360.com/article/patient-safety-organizations-voluntary-relinquishment-for-the-cassatt-patient-sa-6766b6300bea36dfPharma Surgeen2026-07-06T00:00:00.000ZPatient Safety Organizations: Voluntary Relinquishment for the Cassatt Patient Safety Organizationhttps://www.pharmaradar360.com/article/calendar-year-2027-home-health-prospective-payment-system-hh-pps-rate-update-req-3a9334c892e48d51Pharma Surgeen2026-07-06T00:00:00.000ZCalendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Pohttps://www.pharmaradar360.com/article/expedited-investigational-new-drug-pilot-program-request-for-information-correct-2513bdc5da3cf1e1Pharma Surgeen2026-07-06T00:00:00.000ZExpedited Investigational New Drug Pilot Program; Request for Information; Correctionhttps://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-generic-clearance-for-nih-citizen-sci-f5ec33c9d6a787e9Pharma Surgeen2026-07-06T00:00:00.000ZProposed Collection; 60-day Comment Request; Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (Office of the Director)https://www.pharmaradar360.com/article/schedules-of-controlled-substances-temporary-placement-of-mitragynine-pseudoindo-1aa191820c019a08Pharma Surgeen2026-07-06T00:00:00.000ZSchedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule Ihttps://www.pharmaradar360.com/article/schedules-of-controlled-substance-temporary-placement-of-7-hydroxymitragynine-ab-eabb6b75cd05a680Pharma Surgeen2026-07-06T00:00:00.000ZSchedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule Ihttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-360d8559fb466d0dPharma Surgeen2026-07-06T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-2a64b20c2642d6d5Pharma Surgeen2026-07-06T00:00:00.000ZProposed Data Collection Submitted for Public Comment and Recommendationshttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-4298c7d56bd0f39fPharma Surgeen2026-07-06T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-c32590e3f5bd7295Pharma Surgeen2026-07-06T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearingshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-bio-c4bbe26b4f6c5b34Pharma Surgeen2026-07-06T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirementshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-3f7ab81c9f30ed02Pharma Surgeen2026-07-06T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Deviceshttps://www.pharmaradar360.com/article/determination-that-vasopressin-in-sodium-chloride-vasopressin-0-9-injection-50-u-c7aba6861bc2d564Pharma Surgeen2026-07-06T00:00:00.000ZDetermination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/meps-supportive-of-draft-biotech-report-but-divisions-over-incentives-remain-fff282b603d604e9Pharma Surgeen2026-07-05T16:21:39.000ZMEPs supportive of draft Biotech report, but divisions over incentives remainhttps://www.pharmaradar360.com/article/ihe-vs-pjp-which-pharmaceutical-etf-is-the-better-buy-for-investors-1688a53a9f740efcPharma Surgeen2026-07-05T15:44:32.000ZIHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?https://www.pharmaradar360.com/article/biotech-stocks-are-surging-in-2026-this-one-stands-out-after-a-pullback-626f44075305061aPharma Surgeen2026-07-05T15:15:00.000ZBiotech Stocks Are Surging in 2026. This One Stands Out After a Pullback.https://www.pharmaradar360.com/article/price-to-sales-forward-of-collegium-pharmaceutical-inc-fwb-354-b43a7e826ec97bddPharma Surgeen2026-07-05T14:42:33.000ZPrice to sales forward of Collegium Pharmaceutical, Inc. – FWB:354https://www.pharmaradar360.com/article/price-to-book-forward-of-china-resources-jiangzhong-pharmaceutical-co-ltd-class-fd4c6270a154603fPharma Surgeen2026-07-05T14:23:21.000ZPrice to book forward of China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A – SSE:600750https://www.pharmaradar360.com/article/roche-reports-positive-phase-3-results-for-divarasib-in-previously-treated-kras-2eabe1a7abcc5efePharma Surgeen2026-07-05T14:15:04.000ZRoche Reports Positive Phase 3 Results for Divarasib in Previously Treated KRAS G12C NSCLChttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-ctt-pharmaceutical-holdings-inc-otc-ctth-81294a0696c4041dPharma Surgeen2026-07-05T14:13:33.000ZPrice to earnings forward of CTT Pharmaceutical Holdings, Inc. – OTC:CTTHhttps://www.pharmaradar360.com/article/maharashtra-fda-flags-three-beauty-creams-over-toxic-mercury-and-lead-levels-42396aaeb2809a02Pharma Surgeen2026-07-05T13:44:23.000ZMaharashtra FDA Flags Three Beauty Creams Over Toxic Mercury and Lead Levelshttps://www.pharmaradar360.com/article/maharashtra-fda-warns-against-three-beauty-creams-after-tests-detect-excessive-m-e18e9f0f5dd43c0dPharma Surgeen2026-07-05T13:39:09.000ZMaharashtra FDA warns against three beauty creams after tests detect excessive mercury, lead levelshttps://www.pharmaradar360.com/article/fidelity-health-care-vs-state-street-biotech-which-etf-fits-your-portfolio-best-911217dff7804f89Pharma Surgeen2026-07-05T13:35:01.000ZFidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?https://www.pharmaradar360.com/article/gni-group-acquires-ayumi-pharmaceutical-for-jpy-44-8-billion-about-276-million-25a51d94eb4252d8Pharma Surgeen2026-07-05T13:22:22.000ZGNI Group Acquires Ayumi Pharmaceutical For JPY 44.8 Billion (About $276 Million)https://www.pharmaradar360.com/article/viatris-vtrs-most-undervalued-nasdaq-stocks-to-buy-right-now-1ceefbec1c56a272Pharma Surgeen2026-07-05T13:18:09.000ZViatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Nowhttps://www.pharmaradar360.com/article/ai-is-transforming-drug-discovery-here-is-the-next-trillion-dollar-biotech-oppor-e8a5a156d9d7f02ePharma Surgeen2026-07-05T12:38:22.000ZAI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunityhttps://www.pharmaradar360.com/article/883035-forecast-price-target-prediction-for-2027-0148ec38e640e494Pharma Surgeen2026-07-05T12:15:10.000Z883035 Forecast — Price Target — Prediction for 2027https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-collegium-pharmaceutical-inc-nasdaq-coll-7c3715c36593e325Pharma Surgeen2026-07-05T11:54:16.000ZEnterprise value to revenue forward of Collegium Pharmaceutical, Inc. – NASDAQ:COLLhttps://www.pharmaradar360.com/article/cphi-south-east-asia-2026-to-drive-pharma-partnerships-across-asean-eb53ca0c027965d2Pharma Surgeen2026-07-05T11:22:15.000ZCPHI South East Asia 2026 to drive pharma partnerships across ASEANhttps://www.pharmaradar360.com/article/needs-to-be-strengthened-maharashtra-food-regulator-chief-on-manpower-8acb00229e1fb6c6Pharma Surgeen2026-07-05T09:52:40.000Z"Needs To Be Strengthened": Maharashtra Food Regulator Chief On Manpowerhttps://www.pharmaradar360.com/article/maharashtra-bans-pak-beauty-cream-with-mercury-lead-level-above-safe-limit-18-wo-5df2982ea5c4f5d6Pharma Surgeen2026-07-05T09:39:09.000ZMaharashtra bans Pak beauty cream with mercury & lead level above safe limit, 18 women fall illhttps://www.pharmaradar360.com/article/price-to-book-forward-of-taiyen-biotech-co-ltd-twse-1737-bfb7d68f69dc114aPharma Surgeen2026-07-05T09:02:15.000ZPrice to book forward of Taiyen Biotech Co. Ltd. – TWSE:1737https://www.pharmaradar360.com/article/biotech-etf-bbc-touches-a-new-52-week-high-652d3bda4c4af155Pharma Surgeen2026-07-05T08:47:38.000ZBiotech ETF (BBC) touches a new 52-week highhttps://www.pharmaradar360.com/article/fjarde-ap-fonden-fourth-swedish-national-pension-fund-boosts-stake-in-teva-pharm-751d7e5541dafe94Pharma Surgeen2026-07-05T08:04:58.000ZFjarde AP Fonden Fourth Swedish National Pension Fund Boosts Stake in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-zhejiang-jolly-pharmaceutical-co-ltd-class-a-szse-3-a512fd742ac9c6d7Pharma Surgeen2026-07-05T07:51:54.000ZPrice to earnings forward of Zhejiang Jolly Pharmaceutical Co., Ltd. Class A – SZSE:300181https://www.pharmaradar360.com/article/zhejiang-huahai-pharmaceutical-sees-h1-net-profit-up-85-95-y-y-321fda51b4ad51f0Pharma Surgeen2026-07-05T07:50:54.000ZZhejiang Huahai Pharmaceutical Sees H1 Net Profit Up 85-95% Y/Yhttps://www.pharmaradar360.com/article/video-254-exciting-news-apitegromab-phase-3-trial-updates-raven-johnson-zpfmnqen-1b17109b309287d2Pharma Surgeen2026-07-05T07:42:58.000ZVideo #254 - EXCITING NEWS - Apitegromab Phase 3 Trial Updates Raven Johnson (ZpFMNQeNv4)https://www.pharmaradar360.com/article/gsk-acquires-nuvalent-for-10-6-billion-in-oncology-push-f25e48e82de10623Pharma Surgeen2026-07-05T07:40:42.000ZGSK acquires Nuvalent for $10.6 billion in oncology pushhttps://www.pharmaradar360.com/article/bay-area-biotech-giant-to-lay-off-103-employees-f9672130e758bd10Pharma Surgeen2026-07-05T06:19:31.000ZBay Area biotech giant to lay off 103 employeeshttps://www.pharmaradar360.com/article/kazakhstan-india-strengthen-pharmaceutical-partnership-with-new-investment-push-09aaa4caef287460Pharma Surgeen2026-07-05T06:14:07.000ZKazakhstan, India Strengthen Pharmaceutical Partnership with New Investment Pushhttps://www.pharmaradar360.com/article/residents-in-eastern-congo-cling-to-hope-as-a-new-ebola-treatment-trial-begins-e9ac5afdb17835baPharma Surgeen2026-07-05T06:10:10.000ZResidents in eastern Congo cling to hope as a new Ebola treatment trial beginshttps://www.pharmaradar360.com/article/how-much-could-1-000-invested-in-viking-therapeutics-be-worth-by-2030-80782cf159bd6ca2Pharma Surgeen2026-07-05T06:05:00.000ZHow Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?https://www.pharmaradar360.com/article/price-to-book-forward-of-zhejiang-hisoar-pharmaceutical-co-ltd-class-a-szse-0020-34366910c5b8eb81Pharma Surgeen2026-07-05T05:56:47.000ZPrice to book forward of Zhejiang Hisoar Pharmaceutical Co., Ltd. Class A – SZSE:002099https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-zhejiang-jolly-pharmaceutical-co-ltd-class-a-ad7f0fbe981632e5Pharma Surgeen2026-07-05T05:46:53.000ZEnterprise value to EBIT forward of Zhejiang Jolly Pharmaceutical Co., Ltd. Class A – SZSE:300181https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-shanghai-fosun-pharmaceutical-group-co-lt-05fec87fe0df3d16Pharma Surgeen2026-07-05T05:46:22.000ZEnterprise value to revenue forward of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A – SSE:600196https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-touyun-biotech-group-limited-hkex-1332-4aa7e8f9b890045dPharma Surgeen2026-07-05T05:41:23.000ZEnterprise value to EBIT forward of Touyun Biotech Group Limited – HKEX:1332https://www.pharmaradar360.com/article/price-to-sales-forward-of-touyun-biotech-group-limited-hkex-1332-df6f3dd5fa7db0f4Pharma Surgeen2026-07-05T04:50:18.000ZPrice to sales forward of Touyun Biotech Group Limited – HKEX:1332https://www.pharmaradar360.com/article/etfs-investing-in-dizal-pharmaceutical-co-ltd-class-a-stocks-16e98cbd01462d94Pharma Surgeen2026-07-05T04:47:31.000ZETFs Investing in Dizal Pharmaceutical Co Ltd. Class A Stockshttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-central-pharmaceutical-jsc-no-3-hnx-dp3-fee30750b4d8dd2fPharma Surgeen2026-07-05T04:28:07.000ZEnterprise value to EBIT forward of Central Pharmaceutical JSC No. 3 – HNX:DP3https://www.pharmaradar360.com/article/price-to-earnings-forward-of-touyun-biotech-group-limited-hkex-1332-dea219fbff458d15Pharma Surgeen2026-07-05T04:19:11.000ZPrice to earnings forward of Touyun Biotech Group Limited – HKEX:1332https://www.pharmaradar360.com/article/psychedelic-nation-psilocybin-treatments-offer-new-hope-for-people-prozac-hasn-t-0325c7264e55ad44Pharma Surgeen2026-07-05T04:01:00.000ZPsychedelic Nation? Psilocybin Treatments Offer New Hope for People Prozac Hasn’t Helpedhttps://www.pharmaradar360.com/article/aribio-accelerates-global-commercialization-of-alzheimers-drug-ar1001-with-strat-8f0afda535f5327dPharma Surgeen2026-07-05T03:48:00.000ZAribio Accelerates Global Commercialization of Alzheimers Drug AR1001 with Strategic Investmenthttps://www.pharmaradar360.com/article/existing-drug-could-speed-new-treatment-for-rare-liver-cancer-7f47aa32206892f8Pharma Surgeen2026-07-05T03:45:23.000ZExisting drug could speed new treatment for rare liver cancerhttps://www.pharmaradar360.com/article/doctor-at-ou-health-leads-new-clinical-trial-for-stage-1-lung-cancer-patients-21bc3ca66da6ac95Pharma Surgeen2026-07-05T03:44:08.000ZDoctor at OU Health leads new clinical trial for stage 1 lung cancer patientshttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-mochida-pharmaceutical-co-ltd-tse-4534-0b6244892d5f65fdPharma Surgeen2026-07-05T03:42:47.000ZEnterprise value to EBIT forward of Mochida Pharmaceutical Co., Ltd. – TSE:4534https://www.pharmaradar360.com/article/soun-stock-rebounds-after-liveperson-deal-retail-bulls-bank-on-ai-opportunity-wi-cc0dbe5068994023Pharma Surgeen2026-07-05T03:30:33.000ZSOUN Stock Rebounds After LivePerson Deal: Retail Bulls Bank On AI Opportunity With Expanded Fortune 100 Client Basehttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-meribank-biotech-co-ltd-tpex-4724-9e40e66f7e73afc0Pharma Surgeen2026-07-05T03:27:10.000ZEnterprise value to EBIT forward of Meribank Biotech Co Ltd – TPEX:4724https://www.pharmaradar360.com/article/biib-stock-ends-3-higher-why-this-strategist-picks-biogen-over-other-biotech-pee-c961ecccbe965512Pharma Surgeen2026-07-05T03:17:03.000ZBIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peershttps://www.pharmaradar360.com/article/price-to-sales-forward-of-mochida-pharmaceutical-co-ltd-fwb-mfy-d89dbad90d8be7c1Pharma Surgeen2026-07-05T02:49:31.000ZPrice to sales forward of Mochida Pharmaceutical Co., Ltd. – FWB:MFYhttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-group-sehk-3692-wins-trial-approval-is-it-fully-priced-a1a14f4cafae801bPharma Surgeen2026-07-05T02:42:53.000ZHansoh Pharmaceutical Group (SEHK:3692) Wins Trial Approval, Is It Fully Priced?https://www.pharmaradar360.com/article/price-to-earnings-forward-of-mochida-pharmaceutical-co-ltd-fwb-mfy-d81c9163bc32c267Pharma Surgeen2026-07-05T02:28:03.000ZPrice to earnings forward of Mochida Pharmaceutical Co., Ltd. – FWB:MFYhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-mochida-pharmaceutical-co-ltd-fwb-mfy-ba3ce367234ca90bPharma Surgeen2026-07-05T02:23:57.000ZEnterprise value to revenue forward of Mochida Pharmaceutical Co., Ltd. – FWB:MFYhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-tiansheng-pharmaceutical-group-co-ltd-class-a-szse-002-734f9ed55c153186Pharma Surgeen2026-07-05T02:22:40.000ZPrice to sales forward of Tiansheng Pharmaceutical Group Co. Ltd. Class A – SZSE:002872https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-agimexpharm-pharmaceutical-joint-stock-co-dd1d4eb0a7457c13Pharma Surgeen2026-07-05T02:07:46.000ZEnterprise value to EBITDA forward of Agimexpharm Pharmaceutical Joint Stock Co – UPCOM:AGPhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-taiyen-biotech-co-ltd-twse-1737-f2fbe5be5932109fPharma Surgeen2026-07-05T02:03:36.000ZEnterprise value to revenue forward of Taiyen Biotech Co. Ltd. – TWSE:1737https://www.pharmaradar360.com/article/shaanxi-micot-pharmaceutical-technology-co-ltd-class-h-revenue-breakdown-hkex-23-ebaed7eae05596bePharma Surgeen2026-07-05T02:03:24.000ZShaanxi Micot Pharmaceutical Technology Co., Ltd. Class H Revenue Breakdown – HKEX:2335https://www.pharmaradar360.com/article/daily-brief-thematic-sector-industry-apac-healthcare-weekly-july-5-cspc-and-more-0d84d27130f13c68Pharma Surgeen2026-07-05T02:00:55.000ZDaily Brief Thematic (Sector/Industry): APAC Healthcare Weekly (July 5) – CSPC and morehttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-taiyen-biotech-co-ltd-twse-1737-8ac3a0321265246cPharma Surgeen2026-07-05T02:00:36.000ZPrice to earnings forward of Taiyen Biotech Co. Ltd. – TWSE:1737https://www.pharmaradar360.com/article/price-to-sales-forward-of-great-novel-therapeutics-biotech-medicals-corp-tpex-74-0bf51be9aba16ad4Pharma Surgeen2026-07-05T01:46:54.000ZPrice to sales forward of Great Novel Therapeutics Biotech & Medicals Corp. – TPEX:7427https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-agimexpharm-pharmaceutical-joint-stock-co-up-939f0aaaa180185ePharma Surgeen2026-07-05T01:33:01.000ZEnterprise value to EBIT forward of Agimexpharm Pharmaceutical Joint Stock Co – UPCOM:AGPhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-zhejiang-jolly-pharmaceutical-co-ltd-clas-7d86908e02257244Pharma Surgeen2026-07-05T01:26:28.000ZEnterprise value to revenue forward of Zhejiang Jolly Pharmaceutical Co., Ltd. Class A – SZSE:300181https://www.pharmaradar360.com/article/veraxa-biotech-vrxa-stock-price-news-analysis-2b09819439ca80fePharma Surgeen2026-07-05T01:25:37.000ZVeraxa Biotech (VRXA) Stock Price, News & Analysishttps://www.pharmaradar360.com/article/apac-healthcare-weekly-july-5-cspc-abbisko-insilico-takeda-nippon-shinyaku-otsuk-16b5226e55398fe9Pharma Surgeen2026-07-05T00:49:00.000ZAPAC Healthcare Weekly (July 5) – CSPC, Abbisko, Insilico, Takeda, Nippon Shinyaku, Otsuka, CSLhttps://www.pharmaradar360.com/article/new-chongqing-institute-aims-to-turn-biotech-research-into-commercial-products-2f2d6d9183e28d01Pharma Surgeen2026-07-05T00:41:52.000ZNew Chongqing Institute Aims to Turn Biotech Research into Commercial Productshttps://www.pharmaradar360.com/article/price-to-sales-forward-of-taiyen-biotech-co-ltd-twse-1737-67914b1b7891bc39Pharma Surgeen2026-07-05T00:39:21.000ZPrice to sales forward of Taiyen Biotech Co. Ltd. – TWSE:1737https://www.pharmaradar360.com/article/price-to-earnings-forward-of-agimexpharm-pharmaceutical-joint-stock-co-upcom-agp-520990e808b49809Pharma Surgeen2026-07-05T00:25:24.000ZPrice to earnings forward of Agimexpharm Pharmaceutical Joint Stock Co – UPCOM:AGPhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-hunan-hansen-pharmaceutical-co-ltd-class-a-szse-002-9b62456478e43a07Pharma Surgeen2026-07-05T00:07:54.000ZPrice to earnings forward of Hunan Hansen Pharmaceutical Co., Ltd. Class A – SZSE:002412https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-6895452208f7848dPharma Surgeen2026-07-05T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-f75bbd98310a9f85Pharma Surgeen2026-07-05T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-7df13fcf397be3b3Pharma Surgeen2026-07-05T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-07423728b5e42373Pharma Surgeen2026-07-05T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-b57627954c06677ePharma Surgeen2026-07-05T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-67ead14905d8a4ffPharma Surgeen2026-07-05T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-cbcddf7768230ca2Pharma Surgeen2026-07-05T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-0407ef2f5446f927Pharma Surgeen2026-07-05T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-d8b07c415b32105bPharma Surgeen2026-07-05T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-d06ff912a7f3b163Pharma Surgeen2026-07-05T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-2075cf3ae61464cePharma Surgeen2026-07-05T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-d93973ece15eb74dPharma Surgeen2026-07-05T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-55d88dc1dacf73d0Pharma Surgeen2026-07-05T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-3c800f2f83503d4aPharma Surgeen2026-07-05T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/three-dimensional-preoperative-planning-in-reverse-shoulder-arthroplasty-a-syste-2227248f6d5debe2Pharma Surgeen2026-07-05T00:00:00.000ZThree-Dimensional Preoperative Planning in Reverse Shoulder Arthroplasty: A Systematic Review of Implant Positioning Accuracy and Clinical Outcomeshttps://www.pharmaradar360.com/article/metabolomic-biomarkers-for-the-early-detection-of-infectious-diseases-a-systemat-69d6991b5da081eaPharma Surgeen2026-07-05T00:00:00.000ZMetabolomic Biomarkers for the Early Detection of Infectious Diseases: A Systematic Review and Meta-Analysis of Diagnostic Performance and Clinical Utilityhttps://www.pharmaradar360.com/article/colistin-resistance-in-klebsiella-pneumoniae-mechanisms-detection-and-clinical-i-e590b55b2ab5e6abPharma Surgeen2026-07-05T00:00:00.000ZColistin Resistance in Klebsiella pneumoniae: Mechanisms, Detection, and Clinical Impacthttps://www.pharmaradar360.com/article/construction-and-effectiveness-study-of-a-marketing-excellence-system-for-multin-fff6340ef8ff2dffPharma Surgeen2026-07-05T00:00:00.000ZConstruction and Effectiveness Study of a Marketing Excellence System for Multinational Pharmaceutical Companies Under the Dual Drive of Compliance and Digitalizationhttps://www.pharmaradar360.com/article/efficacy-and-schedule-of-ivermectin-in-vivo-against-naturally-acquired-infestati-180aeb530ad71199Pharma Surgeen2026-07-05T00:00:00.000ZEfficacy and schedule of Ivermectin in vivo against naturally acquired infestation of Sarcoptes scabiei on wild red foxes (Vulpes vulpes) treated in a controlled veterinary / clinical rehabilitation environmenthttps://www.pharmaradar360.com/article/clinical-recovery-from-multidrug-resistant-bacterial-infection-in-a-suppurative-dc48dcde53c65b24Pharma Surgeen2026-07-05T00:00:00.000ZClinical recovery from multidrug-resistant bacterial infection in a suppurative wound of a Royal Bengal Tiger using linezolidhttps://www.pharmaradar360.com/article/long-term-clinical-effectiveness-of-early-versus-late-orthodontic-intervention-0759099071e41971Pharma Surgeen2026-07-05T00:00:00.000ZLong-term Clinical Effectiveness of Early Versus Late Orthodontic Interventionhttps://www.pharmaradar360.com/article/ethical-considerations-in-clinical-research-in-prasuti-tantra-and-stree-roga-a-c-b445018338847514Pharma Surgeen2026-07-05T00:00:00.000ZEthical Considerations in Clinical Research in Prasuti Tantra and Stree Roga: A Comprehensive Review of Ayurvedic Interventions During Pregnancy and Women's Reproductive Healthhttps://www.pharmaradar360.com/article/tetrahydropyrimidine-5-carboxylate-attenuates-experimentally-induced-inflammatio-218d281fd237d7b6Pharma Surgeen2026-07-05T00:00:00.000ZTetrahydropyrimidine-5-carboxylate attenuates experimentally induced inflammation through regulation of inflammatory and oxidative stress biomarkers in Wistar ratshttps://www.pharmaradar360.com/article/population-pharmacokinetics-of-piperacillin-in-non-critically-ill-hospitalized-p-fecfa1537b8dd0fePharma Surgeen2026-07-05T00:00:00.000ZPopulation pharmacokinetics of piperacillin in non-critically Ill hospitalized patients: A study from Pakistanhttps://www.pharmaradar360.com/article/dynamic-evolution-prediction-and-patient-stratification-of-chemotherapy-induced-0c40c80095b3963cPharma Surgeen2026-07-05T00:00:00.000ZDynamic evolution, prediction and patient stratification of chemotherapy-induced neutropenia in a predominantly breast cancer cohort: A decision-support study for building a bundle care strategyhttps://www.pharmaradar360.com/article/effects-of-levofloxacin-eye-drops-on-ocular-surface-bacterial-colonization-and-p-8169288b67b621d5Pharma Surgeen2026-07-05T00:00:00.000ZEffects of levofloxacin eye drops on ocular surface bacterial colonization and postoperative infection rate in patients undergoing blepharoplasthttps://www.pharmaradar360.com/article/the-metabolic-blind-spot-bridging-the-gap-between-clinical-medicine-and-nutritio-6498e6f76cf5b9c8Pharma Surgeen2026-07-05T00:00:00.000ZThe Metabolic Blind Spot: Bridging the Gap between Clinical Medicine and Nutritional Sciencehttps://www.pharmaradar360.com/article/resurgence-of-influenza-following-the-lifting-of-non-pharmaceutical-intervention-1feb58d86bdb1f07Pharma Surgeen2026-07-05T00:00:00.000ZResurgence of Influenza Following the Lifting of Non-pharmaceutical Interventions in Shenzhen, Chinahttps://www.pharmaradar360.com/article/latent-profiles-of-teaching-self-efficacy-and-clinical-teaching-behaviors-among-a45d8d50eb5e14c3Pharma Surgeen2026-07-05T00:00:00.000ZLatent Profiles of Teaching Self-Efficacy and Clinical Teaching Behaviors Among Clinical Nurse Preceptors and Factors Associated With Profile Membership: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/talking-with-the-book-not-just-at-children-a-cluster-randomized-trial-of-dialogi-af9a8f82f1c8bb04Pharma Surgeen2026-07-05T00:00:00.000ZTalking With the Book, Not Just at Children: A Cluster-Randomized Trial of Dialogic Reading in Luganda Primary 1 Classroomshttps://www.pharmaradar360.com/article/the-effects-of-cash-transfers-subsidized-childcare-and-life-skills-training-on-a-1c9639dfda4a82daPharma Surgeen2026-07-05T00:00:00.000ZThe effects of cash transfers, subsidized childcare, and life skills training on adolescent mothers' participation in school or vocational training in Malawi: evidence from the PROMOTE project pilot randomized controlled trialhttps://www.pharmaradar360.com/article/reliability-and-clinical-accuracy-of-chatgpt-in-post-fess-counselling-a-multi-re-e0c4351f790d7074Pharma Surgeen2026-07-05T00:00:00.000ZReliability and Clinical Accuracy of ChatGPT in Post-FESS Counselling: A Multi-Reviewer Evaluation.https://www.pharmaradar360.com/article/clinical-validation-of-orthodontic-oral-health-literacy-and-behavior-tools-ohl-o-c820888afa489500Pharma Surgeen2026-07-05T00:00:00.000ZClinical Validation of Orthodontic Oral Health Literacy and Behavior Tools (OHL-Ortho &amp;amp; OHB): A Cross-Sectional Assessment Using CPITN, OHI-S and Objective Knowledge Measureshttps://www.pharmaradar360.com/article/nail-biting-in-children-with-adhd-exploring-its-clinical-correlates-psychiatric-d1e553430d2807c3Pharma Surgeen2026-07-05T00:00:00.000ZNail Biting in Children With ADHD: Exploring Its Clinical Correlates, Psychiatric Comorbidities and Association With Other Body-focused Repetitive Behaviorshttps://www.pharmaradar360.com/article/maternal-risk-factors-and-short-term-clinical-outcomes-of-different-small-vulner-b5d1424311324a16Pharma Surgeen2026-07-05T00:00:00.000ZMaternal Risk Factors and Short-Term Clinical Outcomes of Different Small Vulnerable Newborn (SVN) Phenotypes: A Retrospective Cohort Study of 998 Caseshttps://www.pharmaradar360.com/article/generosity-access-frictions-and-the-win-win-region-in-pharmaceutical-markets-995e3f132956123fPharma Surgeen2026-07-05T00:00:00.000ZGenerosity, Access Frictions, and the Win–Win Region in Pharmaceutical Markets (*)https://www.pharmaradar360.com/article/understanding-eating-behaviors-in-obesity-a-debq-based-analysis-of-clinical-and-be9c348c0db124d4Pharma Surgeen2026-07-05T00:00:00.000ZUnderstanding eating behaviors in obesity: a DEBQ-based analysis of clinical and demographic factorshttps://www.pharmaradar360.com/article/sequential-anaphylaxis-and-delayed-rituximab-induced-serum-sickness-with-skin-te-f47f0dee0bd8c959Pharma Surgeen2026-07-05T00:00:00.000ZSequential anaphylaxis and delayed rituximab-induced serum sickness with skin testing findings: a case reporthttps://www.pharmaradar360.com/article/tca-controlled-histone-succinylation-identifies-idh3b-as-a-prognostic-and-therap-b38d08b3300727d1Pharma Surgeen2026-07-05T00:00:00.000ZTCA-controlled histone succinylation identifies IDH3B as a prognostic and therapeutic target in AMLhttps://www.pharmaradar360.com/article/the-roles-and-clinical-significance-of-linc01140-in-human-cancers-in-the-real-wo-4e34630e005b3c55Pharma Surgeen2026-07-05T00:00:00.000ZThe roles and clinical significance of LINC01140 in human cancers in the real worldhttps://www.pharmaradar360.com/article/proteomic-and-glycosylation-biomarkers-in-rheumatoid-arthritis-advancing-early-d-e752107dfea5f6f6Pharma Surgeen2026-07-05T00:00:00.000ZProteomic and glycosylation biomarkers in rheumatoid arthritis: advancing early diagnosis and precision therapyhttps://www.pharmaradar360.com/article/beyond-biomechanics-advancing-physical-therapy-through-bioenergetic-integration-9f87b74dbdb53bc3Pharma Surgeen2026-07-05T00:00:00.000ZBeyond Biomechanics: Advancing Physical Therapy through Bioenergetic Integration in Clinical Practicehttps://www.pharmaradar360.com/article/a-novel-te-ethosomes-loaded-thermosensitive-gel-for-enhanced-transdermal-deliver-472d0ca298a8f746Pharma Surgeen2026-07-05T00:00:00.000ZA Novel Te-Ethosomes-loaded Thermosensitive Gel for Enhanced Transdermal Delivery and Melasma Therapyhttps://www.pharmaradar360.com/article/tinnitus-hyperacusis-and-somatic-complaints-in-a-diverse-norwegian-clinical-popu-f15a597abf9d3466Pharma Surgeen2026-07-05T00:00:00.000ZTinnitus, hyperacusis and somatic complaints in a diverse Norwegian clinical population: implications for assessment and rehabilitationhttps://www.pharmaradar360.com/article/impact-of-standardized-interdisciplinary-nursing-protocols-on-clinical-outcomes-386c1b012e7880b7Pharma Surgeen2026-07-05T00:00:00.000ZImpact of standardized interdisciplinary nursing protocols on clinical outcomes in neurosurgical patients undergoing craniomaxillofacial reconstruction: a multicenter retrospective studyhttps://www.pharmaradar360.com/article/a-unified-molecular-graph-and-protein-language-model-framework-for-predicting-hu-350a188446e1f2dfPharma Surgeen2026-07-05T00:00:00.000ZA Unified Molecular Graph and Protein Language Model Framework for Predicting Human Drug–Hormone Receptor Interactions with Structure-Aware Validationhttps://www.pharmaradar360.com/article/advancing-biochemical-molecule-registration-representation-and-search-for-new-dr-880d786368d1f786Pharma Surgeen2026-07-05T00:00:00.000ZAdvancing Biochemical Molecule Registration, Representation and Search for New Drug Modalitieshttps://www.pharmaradar360.com/article/unsupervised-image-classification-with-patch-shared-hierarchical-som-on-mnist-an-6467c5233ede6b99Pharma Surgeen2026-07-05T00:00:00.000ZUnsupervised image classification with patch shared hierarchical SOM on MNIST and for clinical blastocyst quality assessmenthttps://www.pharmaradar360.com/article/a-comprehensive-review-of-efficient-deep-learning-for-clinical-medical-imaging-d-661f0cdbfc301881Pharma Surgeen2026-07-05T00:00:00.000ZA comprehensive review of efficient deep learning for clinical medical imaging deploymenthttps://www.pharmaradar360.com/article/effects-of-osteostrong-vs-dynamic-multicomponent-exercise-on-physical-function-i-e632925614f53eabPharma Surgeen2026-07-05T00:00:00.000ZEffects of OsteoStrong vs. dynamic multicomponent exercise on physical function in older women in the BONEMORE randomized controlled trialhttps://www.pharmaradar360.com/article/concordance-between-multidisciplinary-tumor-board-decisions-and-ai-based-recomme-4c2f0737ccb14252Pharma Surgeen2026-07-05T00:00:00.000ZConcordance between multidisciplinary tumor board decisions and AI-based recommendations in endometrial cancer: impact of discordance direction on clinical outcomeshttps://www.pharmaradar360.com/article/transformers-for-3d-medical-image-analysis-a-systematic-review-of-architectural-05b63c7510d8d2bbPharma Surgeen2026-07-05T00:00:00.000ZTransformers for 3D medical image analysis: a systematic review of architectural innovations, performance, and clinical applicationshttps://www.pharmaradar360.com/article/clonal-dynamic-changes-during-the-progression-of-myelodysplastic-neoplasms-to-se-c902c9c15e14743ePharma Surgeen2026-07-05T00:00:00.000ZClonal dynamic changes during the progression of myelodysplastic neoplasms to secondary acute myeloid leukemia: a paired-sample comparisonhttps://www.pharmaradar360.com/article/tfe3-rearranged-pecoma-with-hepatic-and-pulmonary-involvement-diagnostic-challen-9875f80902894fe4Pharma Surgeen2026-07-05T00:00:00.000ZTFE3-rearranged PEComa with hepatic and pulmonary involvement: diagnostic challenges and resistance to mTOR-targeted therapyhttps://www.pharmaradar360.com/article/editorial-for-effect-of-visualized-respiratory-training-on-patient-cooperation-a-c072c60507380bb0Pharma Surgeen2026-07-05T00:00:00.000ZEditorial for “Effect of Visualized Respiratory Training on Patient Cooperation and Image Quality in Gadoxetic Acid Disodium‐Enhanced Liver <scp>MRI</scp> : A Randomized Controlled Trial”https://www.pharmaradar360.com/article/scp-sflt-scp-1-scp-plgf-scp-ratio-in-the-diagnosis-of-preeclampsia-on-the-scp-ma-adbac078ec766912Pharma Surgeen2026-07-05T00:00:00.000Z<scp>sFlt</scp> ‐1/ <scp>PlGF</scp> Ratio in the Diagnosis of Preeclampsia on the <scp>MAGLUMI X3</scp> Analyzerhttps://www.pharmaradar360.com/article/application-of-cell-free-scp-dna-scp-barcode-enabled-single-molecule-test-for-no-7cd0666af489dc1ePharma Surgeen2026-07-05T00:00:00.000ZApplication of Cell‐Free <scp>DNA</scp> Barcode‐Enabled Single‐Molecule Test for Non‐Invasive Prenatal Testing of α‐Thalassemia and β‐Thalassemiahttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-dong-nai-pharmaceutical-joint-stock-co-upcom-58ab195e03195fd6Pharma Surgeen2026-07-04T23:57:22.000ZEnterprise value to EBIT forward of Dong Nai Pharmaceutical Joint Stock Co – UPCOM:DPPhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-hanmi-pharmaceutical-co-ltd-krx-128940-3faa757aa0f62350Pharma Surgeen2026-07-04T23:55:21.000ZEnterprise value to EBIT forward of Hanmi Pharmaceutical Co., Ltd. – KRX:128940https://www.pharmaradar360.com/article/uncy-stock-clocks-worst-day-in-a-year-analysts-keep-buy-ratings-despite-5-12-mon-599e94f6e3084919Pharma Surgeen2026-07-04T23:46:07.000ZUNCY stock clocks worst day in a year — analysts keep buy ratings despite ‘5-12 month delay’ in drug approvalhttps://www.pharmaradar360.com/article/sls-stock-sees-worst-day-in-over-a-month-but-prediction-market-flashes-83-odds-f-05402601967d55b6Pharma Surgeen2026-07-04T23:42:27.000ZSLS Stock Sees Worst Day In Over A Month — But Prediction Market Flashes 83% Odds For November AML Trial Successhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-mochida-pharmaceutical-co-ltd-tse-4534-9b7d1b52659b557cPharma Surgeen2026-07-04T23:42:11.000ZEnterprise value to EBITDA forward of Mochida Pharmaceutical Co., Ltd. – TSE:4534https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-nanjing-pharmaceutical-group-company-limi-468be4fdd7f4166bPharma Surgeen2026-07-04T23:40:02.000ZEnterprise value to revenue forward of Nanjing Pharmaceutical Group Company Limited Class A – SSE:600713https://www.pharmaradar360.com/article/price-to-sales-forward-of-nanjing-pharmaceutical-group-company-limited-class-a-s-ad86f4fca01edc19Pharma Surgeen2026-07-04T23:34:05.000ZPrice to sales forward of Nanjing Pharmaceutical Group Company Limited Class A – SSE:600713https://www.pharmaradar360.com/article/price-to-sales-forward-of-apeloa-pharmaceutical-co-ltd-class-a-szse-000739-97d2b24cec80caacPharma Surgeen2026-07-04T23:09:42.000ZPrice to sales forward of Apeloa Pharmaceutical Co. Ltd. Class A – SZSE:000739https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-apeloa-pharmaceutical-co-ltd-class-a-szse-34092fbe230713daPharma Surgeen2026-07-04T23:08:10.000ZEnterprise value to revenue forward of Apeloa Pharmaceutical Co. Ltd. Class A – SZSE:000739https://www.pharmaradar360.com/article/price-to-sales-forward-of-mochida-pharmaceutical-co-ltd-ls-859288-d36358f8ef8e68f0Pharma Surgeen2026-07-04T23:07:04.000ZPrice to sales forward of Mochida Pharmaceutical Co., Ltd. – LS:859288https://www.pharmaradar360.com/article/price-to-earnings-forward-of-guizhou-yibai-pharmaceutical-co-ltd-class-a-sse-600-ca2145ff6f534d65Pharma Surgeen2026-07-04T23:02:29.000ZPrice to earnings forward of Guizhou Yibai Pharmaceutical Co. Ltd. Class A – SSE:600594https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-nanjing-pharmaceutical-group-company-limit-ff67fe2948b97a53Pharma Surgeen2026-07-04T23:00:54.000ZEnterprise value to EBITDA forward of Nanjing Pharmaceutical Group Company Limited Class A – SSE:600713https://www.pharmaradar360.com/article/fda-approval-for-travere-s-drug-expands-reach-to-broader-rare-kidney-disease-pat-c815948ff08f8dcdPharma Surgeen2026-07-04T22:53:18.000ZFDA approval for Travere's drug expands reach to broader rare kidney disease patientshttps://www.pharmaradar360.com/article/the-buntanetap-program-annovis-bio-bets-on-neurodegeneration-trials-f628fb49113249ebPharma Surgeen2026-07-04T22:38:45.000ZThe buntanetap program - Annovis Bio bets on neurodegeneration trialshttps://www.pharmaradar360.com/article/number-of-shareholders-of-nanjing-pharmaceutical-group-company-limited-class-a-s-98f990b620fa5050Pharma Surgeen2026-07-04T22:37:06.000ZNumber of shareholders of Nanjing Pharmaceutical Group Company Limited Class A – SSE:600713https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-nanjing-pharmaceutical-group-company-limited-0ed8bac2eba6ce39Pharma Surgeen2026-07-04T22:36:26.000ZEnterprise value to EBIT forward of Nanjing Pharmaceutical Group Company Limited Class A – SSE:600713https://www.pharmaradar360.com/article/what-do-moonlake-s-latest-week-40-hs-results-really-mean-for-investors-9f702ce2a4a5c8ffPharma Surgeen2026-07-04T22:34:27.000ZWhat Do MoonLake's Latest Week 40 HS Results Really Mean for Investorshttps://www.pharmaradar360.com/article/global-health-challenges-fda-investigation-ebola-trial-and-brazil-s-antimicrobia-4fcd61e1808f72ebPharma Surgeen2026-07-04T20:59:31.000ZGlobal Health Challenges: FDA Investigation, Ebola Trial, and Brazil's Antimicrobial Compliancehttps://www.pharmaradar360.com/article/why-the-apitegromab-clinical-trial-is-exciting-news-connaught-school-for-girls-s-fba111f5ad6cbea0Pharma Surgeen2026-07-04T20:54:35.000ZWhy The Apitegromab Clinical Trial Is Exciting News Connaught School For Girls Strike (C1BVuIvMaB)https://www.pharmaradar360.com/article/tuhura-biosciences-names-amanda-garofalo-as-clinical-operations-svp-efdcf69d015b937aPharma Surgeen2026-07-04T20:44:20.000ZTuHURA Biosciences names Amanda Garofalo as clinical operations SVPhttps://www.pharmaradar360.com/article/us-researchers-find-widely-used-asthma-drug-impacts-the-brain-cf17fbfe5e4022f1Pharma Surgeen2026-07-04T20:43:58.000ZUS researchers find widely used asthma drug impacts the brainhttps://www.pharmaradar360.com/article/us-probes-germany-s-persistent-underpayment-for-drugs-9f363a1949007336Pharma Surgeen2026-07-04T20:34:01.000ZUS probes Germany's 'persistent underpayment' for drugshttps://www.pharmaradar360.com/article/which-pharmaceutical-etf-is-better-vaneck-s-pph-or-invesco-s-pjp-8ede8b6fe14a32ebPharma Surgeen2026-07-04T20:31:01.000ZWhich Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?https://www.pharmaradar360.com/article/collegium-pharmaceutical-q1-2026-slides-adhd-growth-drives-earnings-beat-5567b77011ee4704Pharma Surgeen2026-07-04T19:29:43.000ZCollegium Pharmaceutical Q1 2026 slides: ADHD growth drives earnings beathttps://www.pharmaradar360.com/article/first-half-2026-recap-endocrinology-17f81b45d58795edPharma Surgeen2026-07-04T19:05:16.000ZFirst Half 2026 Recap - Endocrinologyhttps://www.pharmaradar360.com/article/early-treatment-succeeds-in-crc-with-next-generation-kras-inhibitor-calderasib-p-f8aa07927787d7cePharma Surgeen2026-07-04T18:41:04.000ZEarly Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combohttps://www.pharmaradar360.com/article/sls-stock-hits-over-3-year-high-as-aml-drug-trial-nears-final-readout-wall-stree-d690b1c596b74875Pharma Surgeen2026-07-04T18:39:50.000ZSLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upsidehttps://www.pharmaradar360.com/article/between-two-giants-europe-s-new-oncology-chapter-takes-shape-in-paris-ed399aea4eecfc6ePharma Surgeen2026-07-04T18:02:56.000ZBetween two giants: Europe’s new oncology chapter takes shape in Parishttps://www.pharmaradar360.com/article/maharashtra-bans-sale-of-high-caffeine-energy-drinks-near-schools-a064c850eb9c944cPharma Surgeen2026-07-04T17:02:20.000ZMaharashtra bans sale of high-caffeine energy drinks near schoolshttps://www.pharmaradar360.com/article/5-most-undervalued-nasdaq-stocks-to-buy-right-now-9c63655a4d776e44Pharma Surgeen2026-07-04T17:00:23.000Z5 Most Undervalued NASDAQ Stocks to Buy Right Nowhttps://www.pharmaradar360.com/article/this-biotech-stock-crashed-28-today-after-announcing-second-reverse-share-split-b0b395313df17574Pharma Surgeen2026-07-04T16:43:37.000ZThis Biotech Stock Crashed 28% Today After Announcing Second Reverse Share Split This Yearhttps://www.pharmaradar360.com/article/regeneron-regn-secures-fda-priority-review-and-ema-acceptance-for-cemdisiran-0f5b0dcd7e52c398Pharma Surgeen2026-07-04T16:15:30.000ZRegeneron (REGN) Secures FDA Priority Review And EMA Acceptance For Cemdisiranhttps://www.pharmaradar360.com/article/prosecutors-seek-answers-amid-cooking-oil-scandal-acc04ca7061246baPharma Surgeen2026-07-04T16:00:00.000ZProsecutors seek answers amid cooking oil scandalhttps://www.pharmaradar360.com/article/sellas-life-sciences-78-events-down-two-to-go-the-trial-that-will-settle-the-bul-b35e82260c532c3fPharma Surgeen2026-07-04T15:47:22.000ZSellas Life Sciences: 78 Events Down, Two to Go — The Trial That Will Settle the Bulls vs. Bears Shttps://www.pharmaradar360.com/article/ipsen-acquires-memo-therapeutics-for-up-to-800-million-878863a839487432Pharma Surgeen2026-07-04T14:55:28.000ZIpsen acquires Memo Therapeutics for up to $800 millionhttps://www.pharmaradar360.com/article/doctor-at-ou-health-leads-new-clinical-trial-for-stage-1-lung-cancer-patients-4916613f488c7a16Pharma Surgeen2026-07-04T14:35:02.000ZDoctor at OU Health leads new clinical trial for stage 1 lung cancer patientshttps://www.pharmaradar360.com/article/pune-fda-suspends-food-safety-licences-of-seven-hotels-restaurants-5e5d1dec219394d6Pharma Surgeen2026-07-04T14:25:10.000ZPune FDA Suspends Food Safety Licences of Seven Hotels, Restaurants.https://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32Pharma Surgeen2026-07-04T14:18:52.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/alibaba-to-pay-600m-over-allegations-of-illegal-pharmaceutical-sales-in-the-u-s-835af9ee0490a57bPharma Surgeen2026-07-04T14:00:31.000ZAlibaba to Pay $600M Over Allegations of Illegal Pharmaceutical Sales in the U.S.https://www.pharmaradar360.com/article/the-us-is-hooked-on-unregulated-peptides-but-are-they-effective-or-even-safe-9940d807fbe88a65Pharma Surgeen2026-07-04T14:00:00.000ZThe US is hooked on unregulated peptides. But are they effective, or even safe?https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-sihuan-pharmaceutical-holdings-group-ltd-l-dd86d6aa3aa7a5cfPharma Surgeen2026-07-04T13:55:51.000ZEnterprise value to EBITDA forward of Sihuan Pharmaceutical Holdings Group Ltd. – LSX:A1C72Ghttps://www.pharmaradar360.com/article/vanguard-health-care-vs-ishares-biotech-how-do-these-etfs-stack-up-5a706bfb4567ccb7Pharma Surgeen2026-07-04T13:48:25.000ZVanguard Health Care vs. iShares Biotech: How Do These ETFs Stack Up?https://www.pharmaradar360.com/article/vanguard-health-care-vs-ishares-biotech-how-do-these-etfs-stack-up-8e32e0a9a6c803aaPharma Surgeen2026-07-04T13:35:03.000ZVanguard Health Care vs. iShares Biotech: How Do These ETFs Stack Up?https://www.pharmaradar360.com/article/tsingke-biotech-hosts-shanghai-salon-on-oligonucleotide-drugs-spotlighting-next-0bc57f1a723569e8Pharma Surgeen2026-07-04T13:00:07.000ZTsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeuticshttps://www.pharmaradar360.com/article/fda-is-launching-a-pilot-program-to-shorten-early-drug-trials-and-counter-china-e42cd1d15a2ce244Pharma Surgeen2026-07-04T12:43:13.000ZFDA is launching a pilot program to shorten early drug trials and counter Chinahttps://www.pharmaradar360.com/article/book-value-per-share-of-sunhawk-vision-biotech-inc-tpex-7759-41d2d74bad51a623Pharma Surgeen2026-07-04T12:31:58.000ZBook value per share of Sunhawk Vision Biotech, Inc. – TPEX:7759https://www.pharmaradar360.com/article/tango-therapeutics-stock-surges-on-pancreatic-cancer-trial-data-08d88ddba3aff131Pharma Surgeen2026-07-04T12:30:47.000ZTango Therapeutics stock surges on pancreatic cancer trial datahttps://www.pharmaradar360.com/article/wall-street-thinks-this-high-flying-biotech-stock-can-soar-another-57-85cced41d01a97c2Pharma Surgeen2026-07-04T11:54:11.000ZWall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%https://www.pharmaradar360.com/article/pharmaceutical-manufacturer-relocating-corporate-headquarters-to-cincinnati-b98270dbfd02eb7ePharma Surgeen2026-07-04T11:48:50.000ZPharmaceutical manufacturer relocating corporate headquarters to Cincinnatihttps://www.pharmaradar360.com/article/know-your-company-episode-10-let-s-talk-about-boehringer-ingelheim-msci-world-in-0936d0e57c264b32Pharma Surgeen2026-07-04T11:44:11.000ZKnow Your Company Episode 10 - Let's Talk About Boehringer Ingelheim Msci World Index (QJdK4sNal9)https://www.pharmaradar360.com/article/seven-pune-restaurants-lose-food-licences-as-fda-cracks-down-on-hygiene-violatio-bc968c054ecdc13ePharma Surgeen2026-07-04T11:21:49.000ZSeven Pune Restaurants Lose Food Licences as FDA Cracks Down on Hygiene Violationshttps://www.pharmaradar360.com/article/us-fda-declines-to-approve-unicycive-s-drug-to-treat-elevated-phosphate-levels-i-71eed8509ea5f7b0Pharma Surgeen2026-07-04T10:50:03.000ZUS FDA declines to approve Unicycive's drug to treat elevated phosphate levels in dialysis patientshttps://www.pharmaradar360.com/article/302-995-shares-in-teva-pharmaceutical-industries-ltd-teva-purchased-by-y-interce-ecfd85b585fc22a6Pharma Surgeen2026-07-04T10:35:30.000Z302,995 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Purchased by Y Intercept Hong Kong Ltdhttps://www.pharmaradar360.com/article/maharashtra-schools-to-get-new-food-standards-fda-warns-against-energy-drinks-e301e3ab8b7abf7bPharma Surgeen2026-07-04T09:59:08.000ZMaharashtra schools to get new food standards; FDA warns against 'energy drinks'https://www.pharmaradar360.com/article/is-viking-therapeutics-stock-going-to-50-here-s-what-the-bulls-and-bears-are-say-4c70f16e06fc898bPharma Surgeen2026-07-04T09:51:19.000ZIs Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Sayinghttps://www.pharmaradar360.com/article/tukaram-mundhes-crackdown-fda-suspends-7-pune-food-establishments-over-hygiene-v-c7a6481ad0df7581Pharma Surgeen2026-07-04T09:19:37.000ZTukaram Mundhes Crackdown: FDA Suspends 7 Pune Food Establishments Over Hygiene Violationshttps://www.pharmaradar360.com/article/j-j-s-imaavy-shows-positive-results-in-waiha-trial-by-investing-com-c2d14a2883d5ed71Pharma Surgeen2026-07-04T09:08:46.000ZJ&J’s Imaavy shows positive results in wAIHA trial By Investing.comhttps://www.pharmaradar360.com/article/biomarin-pharmaceutical-inc-nasdaq-bmrn-shows-strong-value-potential-with-a-7-10-7056012337c810cbPharma Surgeen2026-07-04T08:50:37.000ZBioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Ratinghttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-zhejiang-chengyi-pharmaceutical-co-ltd-class-a-sse-2da8c83dd760e670Pharma Surgeen2026-07-04T08:11:01.000ZPrice to earnings forward of Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A – SSE:603811https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-stock-looks-overvalued-despite-upcoming-q2-earn-3ebc3cdf33948b51Pharma Surgeen2026-07-04T08:08:58.000ZWest Pharmaceutical Services (WST) Stock Looks Overvalued Despite Upcoming Q2 Earningshttps://www.pharmaradar360.com/article/price-to-sales-forward-of-haisco-pharmaceutical-group-co-ltd-class-a-szse-002653-368cfeee4f7347d7Pharma Surgeen2026-07-04T08:07:37.000ZPrice to sales forward of Haisco Pharmaceutical Group Co. Ltd. Class A – SZSE:002653https://www.pharmaradar360.com/article/resources-pharmaceutical-stocks-drive-hong-kong-stocks-higher-analyst-1a5ee5a6a063b719Pharma Surgeen2026-07-04T07:56:01.000ZResources, pharmaceutical stocks drive Hong Kong stocks higher: analysthttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-haisco-pharmaceutical-group-co-ltd-class-c14935819b4dd43aPharma Surgeen2026-07-04T07:13:24.000ZEnterprise value to revenue forward of Haisco Pharmaceutical Group Co. Ltd. Class A – SZSE:002653https://www.pharmaradar360.com/article/world-synephrine-hydrochloride-market-analysis-forecast-size-trends-and-insights-8bb7ea960517275aPharma Surgeen2026-07-04T07:11:04.000ZWorld Synephrine Hydrochloride - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/greater-bay-area-emerges-as-launchpad-for-china-s-biotech-rise-3675e582ba5d43edPharma Surgeen2026-07-04T07:09:04.000ZGreater Bay Area emerges as launchpad for China's biotech risehttps://www.pharmaradar360.com/article/vitex-inaugurates-a-250m-wonderland-manufacturing-hub-in-western-sydney-b427ed779d972026Pharma Surgeen2026-07-04T07:00:40.000ZVitex Inaugurates A$250M Wonderland Manufacturing Hub in Western Sydneyhttps://www.pharmaradar360.com/article/new-zealand-passes-landmark-mental-health-law-reform-402071d7c8a708b8Pharma Surgeen2026-07-04T06:53:32.000ZNew Zealand Passes Landmark Mental Health Law Reformhttps://www.pharmaradar360.com/article/ac-immune-amends-lilly-collaboration-plans-tau-drug-studies-152596f4b8db6b1fPharma Surgeen2026-07-04T06:46:49.000ZAC Immune amends Lilly collaboration, plans tau drug studieshttps://www.pharmaradar360.com/article/the-partners-trial-is-running-a-clinical-experiment-that-has-never-been-done-bef-a1d07af684900c93Pharma Surgeen2026-07-04T06:42:26.000ZThe PARTNERS Trial Is Running a Clinical Experiment That Has Never Been Done Before. The World Is Watching.https://www.pharmaradar360.com/article/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-7be94b2b54c2f9d1Pharma Surgeen2026-07-04T06:34:49.000ZSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®https://www.pharmaradar360.com/article/tip127-trofuse-012-a-phase-3-randomized-study-of-adjuvant-sacituzumab-tirumoteca-996c168a52caaa6fPharma Surgeen2026-07-04T06:33:34.000ZTIP127 TroFuse-012: A Phase 3, Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab Vs Treatment of Physician’s Choice in Participants With Triple-Negative Breast Cancer who Received Neoadjuvant Therapy and Did Not Achievehttps://www.pharmaradar360.com/article/immunome-s-4-39-million-insider-sale-a-pre-planned-exit-amidst-robust-pipeline-m-e5cad9ad6541d892Pharma Surgeen2026-07-04T06:07:03.000ZImmunome's $4.39 Million Insider Sale: A Pre-Planned Exit Amidst Robust Pipeline Momentumhttps://www.pharmaradar360.com/article/candel-therapeutics-an-overlooked-late-stage-biotech-with-real-potential-dd57620908978bcaPharma Surgeen2026-07-04T06:06:05.000ZCandel Therapeutics: An Overlooked Late-Stage Biotech With Real Potentialhttps://www.pharmaradar360.com/article/candel-stock-an-overlooked-late-stage-biotech-with-real-potential-nasdaq-cadl-941191180edab203Pharma Surgeen2026-07-04T06:06:05.000ZCandel Stock: An Overlooked Late-Stage Biotech With Real Potential (NASDAQ:CADL)https://www.pharmaradar360.com/article/pune-fda-suspends-licences-of-10-eateries-in-hygiene-safety-crackdown-across-thr-21aa6c7e07b07171Pharma Surgeen2026-07-04T05:47:26.000ZPune FDA suspends licences of 10 eateries in hygiene & safety crackdown across three districtshttps://www.pharmaradar360.com/article/if-you-invested-1-000-in-pharmagreen-biotech-inc-phbi-85c2899557fb833dPharma Surgeen2026-07-04T05:39:50.000ZIf You Invested $1,000 in Pharmagreen Biotech Inc (PHBI)https://www.pharmaradar360.com/article/anthropic-drug-development-plan-for-ai-medicines-da7ad1a7801be055Pharma Surgeen2026-07-04T05:25:44.000ZAnthropic drug development plan for AI medicineshttps://www.pharmaradar360.com/article/fda-suspends-licences-of-six-pune-hotels-over-hygiene-violations-10-establishmen-1173ad27d8a6b103Pharma Surgeen2026-07-04T05:12:48.000ZFDA Suspends Licences of Six Pune Hotels Over Hygiene Violations; 10 Establishments Across Pune Divisionhttps://www.pharmaradar360.com/article/fda-s-sevoflurane-probe-safety-concerns-for-venezuelan-descent-patients-04085c86c8add908Pharma Surgeen2026-07-04T04:59:57.000ZFDA's Sevoflurane Probe: Safety Concerns for Venezuelan Descent Patientshttps://www.pharmaradar360.com/article/maharashtra-enforces-zero-tolerance-policy-on-milk-adulteration-bc2c5913b0bdb986Pharma Surgeen2026-07-04T04:35:01.000ZMaharashtra Enforces Zero-Tolerance Policy on Milk Adulterationhttps://www.pharmaradar360.com/article/abivax-stock-surges-on-obefazimod-safety-data-cancer-concerns-3cb2db2873196cc1Pharma Surgeen2026-07-04T03:53:55.000ZAbivax stock surges on obefazimod safety data, cancer concernshttps://www.pharmaradar360.com/article/price-to-book-forward-of-qingdao-vland-biotech-inc-class-a-sse-603739-3ce7bb1313ca1e30Pharma Surgeen2026-07-04T03:49:11.000ZPrice to book forward of Qingdao Vland Biotech INC. Class A – SSE:603739https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-raphael-pharmaceutical-inc-otc-raph-39338396e60be195Pharma Surgeen2026-07-04T03:38:58.000ZEnterprise value to EBIT forward of RAPHAEL PHARMACEUTICAL INC. – OTC:RAPHhttps://www.pharmaradar360.com/article/fda-suspends-licences-of-seven-pune-eateries-for-food-safety-violations-hindusta-861dd66e8a16e018Pharma Surgeen2026-07-04T03:21:07.000ZFDA suspends licences of seven Pune eateries for food safety violations | Hindustan Timeshttps://www.pharmaradar360.com/article/fda-cracks-down-on-energy-drinks-mumbai-news-84df7bb155deaac5Pharma Surgeen2026-07-04T03:09:36.000ZFDA cracks down on ‘energy drinks’ | Mumbai newshttps://www.pharmaradar360.com/article/etfs-investing-in-zhejiang-hisoar-pharmaceutical-co-ltd-class-a-stocks-e102683174162177Pharma Surgeen2026-07-04T02:48:36.000ZETFs Investing in Zhejiang Hisoar Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/fda-probes-anesthesia-linked-neurological-complications-in-some-patients-of-vene-d62b7edd4a9ab183Pharma Surgeen2026-07-04T02:30:01.000ZFDA probes anesthesia-linked neurological complications in some patients of Venezuelan ancestryhttps://www.pharmaradar360.com/article/etfs-investing-in-nanjing-hicin-pharmaceutical-co-ltd-class-a-stocks-fdd2c3118bf21095Pharma Surgeen2026-07-04T02:16:36.000ZETFs Investing in Nanjing Hicin Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/maharashtra-fda-launches-strict-dairy-safety-crackdown-says-tukaram-mundhe-1fbbfb4ffad7be94Pharma Surgeen2026-07-04T01:51:37.000ZMaharashtra FDA launches strict dairy safety crackdown, says Tukaram Mundhehttps://www.pharmaradar360.com/article/roche-and-nurix-strike-2-3-billion-blood-cancer-drug-deal-5d66e08a13d7d72cPharma Surgeen2026-07-04T01:30:13.000ZRoche and Nurix strike $2.3 billion blood cancer drug dealhttps://www.pharmaradar360.com/article/eli-lilly-stock-jumps-on-retatrutide-phase-3-weight-loss-results-c0fa5f6e9cb28e6ePharma Surgeen2026-07-04T01:30:05.000ZEli Lilly stock jumps on retatrutide Phase 3 weight loss resultshttps://www.pharmaradar360.com/article/abbvie-acquires-apogee-therapeutics-for-10-9-billion-eb4473160c9d9b34Pharma Surgeen2026-07-04T01:17:53.000ZAbbVie acquires Apogee Therapeutics for $10.9 billionhttps://www.pharmaradar360.com/article/etfs-investing-in-jointown-pharmaceutical-group-co-ltd-class-a-stocks-cd730ff1f55e32aePharma Surgeen2026-07-04T01:12:56.000ZETFs Investing in Jointown Pharmaceutical Group Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/the-new-anthropic-tool-that-could-change-how-drugs-are-developed-795cf3bfa403ab0bPharma Surgeen2026-07-04T01:08:30.000ZThe New Anthropic Tool That Could Change How Drugs Are Developedhttps://www.pharmaradar360.com/article/hk-inno-n-reports-record-earnings-driven-by-k-cap-eyes-obesity-drug-development-369cf9953d807b99Pharma Surgeen2026-07-04T01:04:00.000ZHK Inno.N Reports Record Earnings Driven by K-Cap, Eyes Obesity Drug Developmenthttps://www.pharmaradar360.com/article/big-pharma-enters-the-arena-next-generation-in-vivo-car-t-gains-traction-4dbb126ce0c2d655Pharma Surgeen2026-07-04T01:04:00.000ZBig Pharma Enters the Arena: Next-Generation In Vivo CAR-T Gains Tractionhttps://www.pharmaradar360.com/article/etfs-investing-in-tibet-rhodiola-pharmaceutical-holding-co-class-a-stocks-98ac33233aebd102Pharma Surgeen2026-07-04T00:46:59.000ZETFs Investing in Tibet Rhodiola Pharmaceutical Holding Co. Class A Stockshttps://www.pharmaradar360.com/article/zero-tolerance-for-milk-adulteration-maharashtra-issues-statewide-compliance-ord-d87de15e999232f1Pharma Surgeen2026-07-04T00:29:55.000ZZero-tolerance for milk adulteration: Maharashtra issues statewide compliance orderhttps://www.pharmaradar360.com/article/treatment-outcomes-and-adverse-events-associated-with-intermittent-versus-daily-97cf55d8453f1b6ePharma Surgeen2026-07-04T00:00:00.000ZTreatment outcomes and adverse events associated with intermittent versus daily continuation-phase regimens in drug-susceptible tuberculosis patients in Makassar, Indonesia: an observational cohort study.https://www.pharmaradar360.com/article/clinical-immunogenicity-and-pharmacokinetic-assessments-of-e3112-a-recombinant-h-a2d044f618e3a0bdPharma Surgeen2026-07-04T00:00:00.000ZClinical immunogenicity and pharmacokinetic assessments of E3112, a recombinant human hepatocyte growth factor.https://www.pharmaradar360.com/article/personalized-neoantigen-pulsed-autologous-dendritic-cells-in-newly-diagnosed-gli-39ed206ed304f1d2Pharma Surgeen2026-07-04T00:00:00.000ZPersonalized neoantigen-pulsed autologous dendritic cells in newly-diagnosed glioblastoma: a phase Ib trial.https://www.pharmaradar360.com/article/bridging-the-knowledge-practice-gap-in-emergency-care-at-the-primary-healthcare-e244e225b134ec5cPharma Surgeen2026-07-04T00:00:00.000ZBridging the Knowledge - practice Gap in Emergency Care at the Primary Healthcare Level: Evidence from Ahafo Ano North Municipality, Ghanahttps://www.pharmaradar360.com/article/propolis-based-solution-application-in-extraction-socket-healing-a-3d-split-mout-eb0820849921c173Pharma Surgeen2026-07-04T00:00:00.000ZPropolis-Based Solution Application in Extraction Socket Healing: A 3D Split-Mouth Clinical Pilot Studyhttps://www.pharmaradar360.com/article/protocol-for-a-modified-delphi-consensus-study-on-the-clinical-assessment-of-chi-d280ef5decfba9d6Pharma Surgeen2026-07-04T00:00:00.000ZProtocol for a Modified Delphi Consensus Study on the Clinical Assessment of Children with Suspected Olfactory Dysfunctionhttps://www.pharmaradar360.com/article/foundations-and-frontiers-of-naturopathic-diagnosis-integrating-traditional-prin-c9fa3fab649465e9Pharma Surgeen2026-07-04T00:00:00.000ZFoundations and Frontiers of Naturopathic Diagnosis: Integrating Traditional Principles with Clinical Sciencehttps://www.pharmaradar360.com/article/adherence-to-guideline-directed-medical-therapy-and-its-impact-on-clinical-outco-3de13ae4e8050434Pharma Surgeen2026-07-04T00:00:00.000ZAdherence to Guideline-Directed Medical Therapy and its Impact on Clinical Outcomes in Heart Failure Patients Admitted to a Teaching Hospitalhttps://www.pharmaradar360.com/article/factors-associated-with-nurses-early-warning-system-ews-scoring-accuracy-and-pat-13f5dfd00f6730bcPharma Surgeen2026-07-04T00:00:00.000ZFactors Associated with Nurses’ Early Warning System (EWS) Scoring Accuracy and Patient Clinical Outcomeshttps://www.pharmaradar360.com/article/sustainable-approach-towards-multiple-drug-resistance-exploring-the-antiswarming-f79de65a5a6393e1Pharma Surgeen2026-07-04T00:00:00.000ZSustainable Approach Towards Multiple Drug Resistance: Exploring the Antiswarming Potential of Actinobacteria in Search of Novel Metabolites.https://www.pharmaradar360.com/article/stimulants-psychoactive-plants-and-human-optimization-medical-gatekeeping-prohib-1700a17629a79acePharma Surgeen2026-07-04T00:00:00.000ZStimulants, Psychoactive Plants, and Human Optimization: Medical Gatekeeping, Prohibition, and Adult Autonomy in Drug Policyhttps://www.pharmaradar360.com/article/green-products-green-startups-and-commerce-based-innovations-as-catalysts-for-a-ef792c95dc0bdbb2Pharma Surgeen2026-07-04T00:00:00.000ZGreen Products, Green startups and Commerce based Innovations as Catalysts for a Green Economyhttps://www.pharmaradar360.com/article/molding-the-economic-mind-self-selection-indoctrination-and-student-values-in-in-01126b8f5ba35bfcPharma Surgeen2026-07-04T00:00:00.000ZMolding the Economic Mind: Self-Selection, Indoctrination, and Student Values in Indiahttps://www.pharmaradar360.com/article/hypertonicity-and-piezo1-activation-enhance-radiosensitivity-of-b16-melanoma-e1b4a5ffed42e126Pharma Surgeen2026-07-04T00:00:00.000ZHypertonicity and Piezo1 Activation Enhance Radiosensitivity of B16 Melanomahttps://www.pharmaradar360.com/article/impact-of-99mtc-methylene-diphosphonate-single-photon-emission-computed-tomograp-c6963f284ad7e760Pharma Surgeen2026-07-04T00:00:00.000ZImpact of 99mTc-methylene diphosphonate single photon emission computed tomography/computed tomography on management and clinical outcomes in patients with failed back surgery syndromehttps://www.pharmaradar360.com/article/overlapping-clinical-features-of-transfusion-related-acute-lung-injury-and-anaph-d3ca2c2ee1b07beePharma Surgeen2026-07-04T00:00:00.000ZOverlapping clinical features of transfusion-related acute lung injury and anaphylactic shock during general anesthesia: a case reporthttps://www.pharmaradar360.com/article/coenzyme-q10-as-an-adjunctive-strategy-to-reduce-paclitaxel-induced-toxicities-i-88472e00e4102034Pharma Surgeen2026-07-04T00:00:00.000ZCoenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trialhttps://www.pharmaradar360.com/article/advances-in-antibody-drug-conjugates-in-cancer-latest-updates-from-the-2026-aacr-580d0f9d4deb16b8Pharma Surgeen2026-07-04T00:00:00.000ZAdvances in antibody-drug conjugates in cancer: latest updates from the 2026 AACR annual meetinghttps://www.pharmaradar360.com/article/tailor-a-randomised-trial-to-compare-the-clinical-and-cost-effectiveness-of-a-pa-953cc71858f2210cPharma Surgeen2026-07-04T00:00:00.000ZTaILOR: a randomised trial to compare the clinical and cost-effectiveness of a patient-initiated follow-up (PIFU) strategy compared to standard care pathways in people with inflammatory arthritis: a study protocolhttps://www.pharmaradar360.com/article/brief-communication-clinical-jaundice-is-associated-with-poor-adherence-to-boost-f20ad1f92627cb7ePharma Surgeen2026-07-04T00:00:00.000ZBrief communication: clinical jaundice is associated with poor adherence to boosted atazanavir among adults in an HIV clinic in Kampala, Ugandahttps://www.pharmaradar360.com/article/efficacy-of-remote-ischemic-conditioning-on-cerebral-blood-flow-regulation-in-pa-6ef2c3a0918797b4Pharma Surgeen2026-07-04T00:00:00.000ZEfficacy of remote ischemic conditioning on cerebral blood flow regulation in patients with endovascular stenting: a randomized controlled trialhttps://www.pharmaradar360.com/article/development-and-validation-of-a-clinical-prediction-model-for-acupuncture-respon-a3ef199650862d06Pharma Surgeen2026-07-04T00:00:00.000ZDevelopment and validation of a clinical prediction model for acupuncture response in community-dwelling patients with chronic low back pain: a retrospective cohort studyhttps://www.pharmaradar360.com/article/association-between-3-d-ct-based-volumetric-fat-infiltration-of-lumbar-paraspina-55312a9c70dae686Pharma Surgeen2026-07-04T00:00:00.000ZAssociation between 3 D CT-based volumetric fat infiltration of lumbar paraspinal muscles and bone mineral density: a clinical studyhttps://www.pharmaradar360.com/article/effects-of-opioid-free-anesthesia-on-postoperative-anxiety-in-patients-undergoin-a528b50a122d4f9fPharma Surgeen2026-07-04T00:00:00.000ZEffects of opioid-free anesthesia on postoperative anxiety in patients undergoing modified radical mastectomy for breast cancer: a randomized controlled trialhttps://www.pharmaradar360.com/article/supporting-physician-well-being-and-mental-health-clinical-skill-development-eva-8dd593a08423c4c3Pharma Surgeen2026-07-04T00:00:00.000ZSupporting Physician Well-being and Mental Health Clinical Skill Development: Evaluation of Mental Health Skills Groups for Physicianshttps://www.pharmaradar360.com/article/cardiometabolic-screening-elevated-results-and-clinical-follow-up-actions-in-ma-4673fed58245ec15Pharma Surgeen2026-07-04T00:00:00.000ZCardiometabolic screening, elevated results and clinical follow-up actions in Ma-ori and non-Ma-ori with psychosis in Canterbury, Aotearoa New Zealandhttps://www.pharmaradar360.com/article/lenvatinib-versus-sorafenib-in-first-line-treatment-of-older-patients-with-unres-87adb7e96db9f96bPharma Surgeen2026-07-04T00:00:00.000ZLenvatinib Versus Sorafenib in First-Line Treatment of Older Patients With Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trialhttps://www.pharmaradar360.com/article/when-clinical-ai-hallucinates-or-appears-to-a-reflective-account-of-human-ai-dia-578ccebb826cf172Pharma Surgeen2026-07-04T00:00:00.000ZWhen Clinical AI Hallucinates or Appears To: A Reflective Account of Human-AI Diagnostic Interaction in General Practicehttps://www.pharmaradar360.com/article/how-we-study-clinical-documentation-practices-in-the-wild-a-systematic-literatur-3e94c5088a1774c3Pharma Surgeen2026-07-04T00:00:00.000ZHow We Study Clinical Documentation Practices in the Wild: A Systematic Literature Review of CHI and CSCWhttps://www.pharmaradar360.com/article/a-multidimensional-approach-to-usability-engineering-clinical-performance-and-hu-56ef7bc2579f02daPharma Surgeen2026-07-04T00:00:00.000ZA Multidimensional Approach to Usability Engineering, Clinical Performance and Human-AI Interaction in AI-Enabled Medical Deviceshttps://www.pharmaradar360.com/article/dual-coronary-sinus-lead-strategy-to-avoid-tricuspid-valve-traversal-in-biventri-d32eec151fea77ddPharma Surgeen2026-07-04T00:00:00.000ZDual Coronary Sinus Lead Strategy to Avoid Tricuspid Valve Traversal in Biventricular Pacinghttps://www.pharmaradar360.com/article/i-savor-aging-i-the-art-of-savoring-positive-emotions-in-older-adulthood-a-rando-9226514d9e47ccccPharma Surgeen2026-07-04T00:00:00.000Z<i>Savor‐Aging</i> : The Art of Savoring Positive Emotions in Older Adulthood—A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/white-phosphorus-burns-a-comprehensive-review-over-a-century-of-evidence-from-wi-7899415d9784946cPharma Surgeen2026-07-04T00:00:00.000ZWhite Phosphorus Burns: A Comprehensive Review over a Century of Evidence from “Willie Peter” to Modern Clinical Managementhttps://www.pharmaradar360.com/article/clinical-effects-and-safety-of-radiofrequency-microneedling-for-the-management-o-49eef47c814acc1fPharma Surgeen2026-07-04T00:00:00.000ZClinical Effects and Safety of Radiofrequency Microneedling for the Management of Melasma: A Retrospective Studyhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-doravirine-islatravir-for-hiv-1-a-grade-assessed-systemat-d415aa65f92771d4Pharma Surgeen2026-07-04T00:00:00.000ZEfficacy and safety of doravirine/islatravir for HIV-1: a GRADE-assessed systematic review and meta-analysis of randomized controlled trialshttps://www.pharmaradar360.com/article/assessment-of-facial-emotion-recognition-accuracy-and-reaction-time-in-patients-c39385e803d0dd9dPharma Surgeen2026-07-04T00:00:00.000ZAssessment of facial emotion recognition accuracy and reaction time in patients with social anxiety disorder diagnosed with performance-only specifierhttps://www.pharmaradar360.com/article/outcome-specific-prognostic-performance-of-pneumonia-severity-assessment-tools-f-3c2792d75514e6c1Pharma Surgeen2026-07-04T00:00:00.000ZOutcome-Specific Prognostic Performance of Pneumonia Severity Assessment Tools for Predicting a Spectrum of Multiple Clinical Eventshttps://www.pharmaradar360.com/article/cognitive-behavior-therapy-for-functional-neurological-disorder-a-systematic-rev-48934abcefe2f9dbPharma Surgeen2026-07-04T00:00:00.000ZCognitive Behavior Therapy for Functional Neurological Disorder: A Systematic Review of Therapeutic Structure and Clinical Impacthttps://www.pharmaradar360.com/article/production-optimization-of-cellulase-from-bacillus-licheniformis-and-its-applica-212538229a11df79Pharma Surgeen2026-07-04T00:00:00.000ZProduction optimization of cellulase from Bacillus licheniformis and its application in paper pulp modification and biobleachinghttps://www.pharmaradar360.com/article/deciphering-bacterial-wilt-resistance-in-eggplant-identification-of-elite-lines-78ce04c22b64ddc2Pharma Surgeen2026-07-04T00:00:00.000ZDeciphering bacterial wilt resistance in eggplant: identification of elite lines, DNA marker validation and transcriptome profilinghttps://www.pharmaradar360.com/article/antiepileptic-potential-of-salicylhydroxamic-acid-genomic-molecular-docking-and-f98239185f702d23Pharma Surgeen2026-07-04T00:00:00.000ZAntiepileptic potential of salicylhydroxamic acid: genomic, molecular docking, and functional evaluations in pentylenetetrazole-induced adult zebrafishhttps://www.pharmaradar360.com/article/a-philosophical-introduction-to-in-silico-clinical-trials-4f7fccc54964c0f8Pharma Surgeen2026-07-04T00:00:00.000ZA philosophical introduction to in-silico clinical trialshttps://www.pharmaradar360.com/article/efficacy-and-safety-of-second-line-treatments-in-alk-mutation-positive-advanced-c7ec093cb5303f6ePharma Surgeen2026-07-04T00:00:00.000ZEfficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)https://www.pharmaradar360.com/article/salivary-lipid-profile-and-malondialdehyde-levels-in-clinically-healthy-and-peri-284bb0c9100bd4f6Pharma Surgeen2026-07-04T00:00:00.000ZSalivary Lipid Profile and Malondialdehyde Levels in Clinically Healthy and Periodontally Diseased Individualshttps://www.pharmaradar360.com/article/gastrointestinal-dysfunction-in-critically-ill-patients-with-traumatic-brain-inj-4c1ed15e5e085a16Pharma Surgeen2026-07-04T00:00:00.000ZGastrointestinal Dysfunction in Critically Ill Patients With Traumatic Brain Injury: Clinical Implications and Putative Mechanisms: a Narrative Reviewhttps://www.pharmaradar360.com/article/effects-of-adding-kinesiotaping-to-conventional-physiotherapy-on-pain-function-a-4dc674c14a0bc075Pharma Surgeen2026-07-04T00:00:00.000ZEffects of adding Kinesiotaping to conventional physiotherapy on pain, function, and Kinesiophobia in knee osteoarthritis: A randomized controlled trialhttps://www.pharmaradar360.com/article/seroprevalence-of-toxoplasma-gondii-and-feline-immunodeficiency-virus-in-domesti-9f702d50b6ef5804Pharma Surgeen2026-07-04T00:00:00.000ZSeroprevalence of Toxoplasma gondii and Feline Immunodeficiency Virus in Domestic Cats and Their Associations with Clinical Signshttps://www.pharmaradar360.com/article/adaptations-in-electron-transport-chain-complexes-of-clinical-rhodococcus-equi-r-840c698114f418c8Pharma Surgeen2026-07-04T00:00:00.000ZAdaptations in electron transport chain complexes of clinical Rhodococcus equi revealed through comparative genomicshttps://www.pharmaradar360.com/article/stem-cell-based-regenerative-therapies-for-non-ischemic-cardiomyopathy-mechanist-602e4623472cda39Pharma Surgeen2026-07-04T00:00:00.000ZStem cell–based regenerative therapies for non-ischemic cardiomyopathy: mechanistic insights, clinical evidence, and future directionshttps://www.pharmaradar360.com/article/ai-enabled-clinical-decision-support-in-breast-cancer-care-a-blinded-multicenter-8f2283f7aaddc071Pharma Surgeen2026-07-04T00:00:00.000ZAI-enabled clinical decision support in breast cancer care: a blinded multicenter benchmarking study comparing medically specialized with a general-purpose systemhttps://www.pharmaradar360.com/article/intergenerational-income-mobility-and-psychotropic-drug-dispensation-in-a-1953-s-0db72f0732ee5891Pharma Surgeen2026-07-04T00:00:00.000ZIntergenerational income mobility and psychotropic drug dispensation in a 1953 Stockholm cohort: a diagonal reference model approachhttps://www.pharmaradar360.com/article/xrn2-governed-by-rna-binding-protein-ptbp3-promotes-the-invasiveness-of-esophage-62ee0ac514675703Pharma Surgeen2026-07-04T00:00:00.000ZXRN2, governed by RNA-binding protein PTBP3, promotes the invasiveness of esophageal squamous cell carcinomahttps://www.pharmaradar360.com/article/effects-of-quetiapine-on-cognitive-functioning-in-schizophrenia-evidence-for-the-121aca2300d6f423Pharma Surgeen2026-07-04T00:00:00.000ZEffects of quetiapine on cognitive functioning in schizophrenia: evidence for the remyelination hypothesis?https://www.pharmaradar360.com/article/bridging-the-gap-between-validated-cognitive-screening-and-clinical-practice-a-s-041121198c79292cPharma Surgeen2026-07-04T00:00:00.000ZBridging the Gap Between Validated Cognitive Screening and Clinical Practice: A Stylus-Driven Digital Use Case for the SAGE Testhttps://www.pharmaradar360.com/article/effects-of-trimethoprim-on-three-previously-proposed-putative-biomarkers-for-scp-e6b073a783259a91Pharma Surgeen2026-07-04T00:00:00.000ZEffects of Trimethoprim on Three Previously Proposed Putative Biomarkers for <scp>OCT2</scp> / <scp>MATE</scp> ‐Mediated Renal Drug‐Drug Interactions in Healthy Volunteershttps://www.pharmaradar360.com/article/anatomical-fidelity-in-text-to-image-generative-scp-ai-scp-a-comparative-qualita-030a22654ffabdf5Pharma Surgeen2026-07-04T00:00:00.000ZAnatomical Fidelity in Text‐to‐Image Generative <scp>AI</scp> : A Comparative Qualitative and Quantitative Evaluationhttps://www.pharmaradar360.com/article/neuroblastoma-pipeline-accelerates-as-20-pharma-companies-rigorously-develop-dru-688ab04dacc50bb3Pharma Surgeen2026-07-03T23:26:19.000ZNeuroblastoma Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsighthttps://www.pharmaradar360.com/article/sjogren-s-disease-pipeline-accelerates-as-20-pharma-companies-rigorously-develop-396f91fcfa4718edPharma Surgeen2026-07-03T23:26:18.000ZSjögren’s Disease Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsighthttps://www.pharmaradar360.com/article/non-alcoholic-fatty-liver-disease-pipeline-accelerates-as-90-pharma-companies-ri-a7283dd6f16089f7Pharma Surgeen2026-07-03T23:26:16.000ZNon-Alcoholic Fatty Liver Disease Pipeline Accelerates as 90+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsighthttps://www.pharmaradar360.com/article/scholar-rock-positive-top-line-results-from-topaz-trial-type-2-and-3-sma-nicki-m-80d51dbbb6d0f298Pharma Surgeen2026-07-03T23:15:47.000ZScholar Rock - Positive Top-Line Results From TOPAZ Trial - Type 2 And 3 SMA Nicki Minaj (sET9MO52HO)https://www.pharmaradar360.com/article/jyong-biotech-showcases-botanical-drug-portfolio-at-bio-2026-international-conve-cb80f891cb1cdf84Pharma Surgeen2026-07-03T23:15:18.000ZJyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Conventionhttps://www.pharmaradar360.com/article/rigid-vinyl-films-market-forecast-points-higher-toward-2035-driven-by-pharmaceut-8de89b33c17b44afPharma Surgeen2026-07-03T22:46:06.000ZRigid Vinyl Films Market Forecast Points Higher Toward 2035, Driven by Pharmaceutical Blister Packaging Demandhttps://www.pharmaradar360.com/article/etfs-investing-in-china-resources-sanjiu-medical-pharmaceutical-co-ltd-class-a-s-46619644d398610aPharma Surgeen2026-07-03T22:39:11.000ZETFs Investing in China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/the-new-rules-of-biotech-now-available-in-hardcover-and-audiobook-695edce8bcb4ba56Pharma Surgeen2026-07-03T22:20:36.000ZThe New Rules of Biotech Now Available in Hardcover and Audiobook